Total Payments
$239,174
2024 Payments
$22,025
Companies
5
Transactions
209
Medicare Patients
36
Medicare Billing
$9,216
Payment Breakdown by Category
Research$208,100 (87.0%)
Consulting$27,301 (11.4%)
Travel$3,194 (1.3%)
Food & Beverage$578.29 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $208,100 | 176 | 87.0% |
| Consulting Fee | $27,301 | 11 | 11.4% |
| Travel and Lodging | $3,194 | 10 | 1.3% |
| Food and Beverage | $578.29 | 12 | 0.2% |
Payments by Type
Research
$208,100
176 transactions
General
$31,074
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $209,291 | 188 | $0 (2024) |
| Stryker Corporation | $10,846 | 8 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $7,729 | 8 | $0 (2022) |
| Indivior Inc. | $6,169 | 1 | $0 (2017) |
| AstraZeneca UK Limited | $5,138 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,025 | 15 | Novo Nordisk AS ($22,025) |
| 2023 | $52,413 | 38 | Novo Nordisk AS ($47,975) |
| 2022 | $56,675 | 38 | Novo Nordisk AS ($55,475) |
| 2021 | $45,700 | 38 | Novo Nordisk AS ($43,975) |
| 2020 | $35,105 | 43 | Novo Nordisk AS ($30,725) |
| 2019 | $4,175 | 10 | Novo Nordisk AS ($4,175) |
| 2018 | $15,512 | 20 | Stryker Corporation ($9,448) |
| 2017 | $7,568 | 7 | Indivior Inc. ($6,169) |
All Payment Transactions
209 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,700.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/15/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,475.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 09/10/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $450.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 08/13/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $225.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 08/08/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,925.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 07/03/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,675.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/23/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,200.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/23/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,825.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 04/04/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/29/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,775.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/21/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 02/07/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,625.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/07/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 01/19/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,525.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 01/05/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,375.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 12/08/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $525.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 11/28/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,575.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 11/07/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/19/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,150.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/19/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $575.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 10/10/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,150.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/06/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,925.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 09/12/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $775.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX9536-4388 | Novo Nordisk AS | $89,000 | 47 |
| EX9924-4473 | Novo Nordisk AS | $80,325 | 59 |
| NN9535-4321 | Novo Nordisk AS | $31,600 | 48 |
| NN9536-4374 | Novo Nordisk AS | $2,950 | 5 |
| NN9535-4533 | Novo Nordisk AS | $2,225 | 7 |
| NN9536-4373 | Novo Nordisk AS | $900.00 | 5 |
| NN9536-4379 | Novo Nordisk AS | $375.00 | 1 |
| A Multicentre Randomised Double blind Parallel Group Placebo controlled Phase 3 Efficacy and Safety Study of Benralizumab MEDI563 Added to Medium to High dose Inhaled Corticosteroid Plus Long-acting b2 Agonist in Patients with Uncontrolled Asthma MIRACLE | AstraZeneca UK Limited | $350.00 | 1 |
| NN9536-4376 | Novo Nordisk AS | $125.00 | 1 |
| NN9536-4378 | Novo Nordisk AS | $125.00 | 1 |
| NN9536-4382 | Novo Nordisk AS | $125.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 3 | 36 | 108 | $26,982 | $9,216 |
Total Patients
36
Total Services
108
Medicare Billing
$9,216
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 41 | $10,551 | $3,722 | 35.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 56 | $10,510 | $3,543 | 33.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $5,921 | $1,951 | 33.0% |
About Kyra Becker
Kyra Becker is a Neurology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902985666.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kyra Becker has received a total of $239,174 in payments from pharmaceutical and medical device companies, with $22,025 received in 2024. These payments were reported across 209 transactions from 5 companies. The most common payment nature is "" ($208,100).
As a Medicare-enrolled provider, Becker has provided services to 36 Medicare beneficiaries, totaling 108 services with total Medicare billing of $9,216. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Seattle, WA
- Active Since 11/03/2006
- Last Updated 01/12/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1902985666
Products in Payments
- Wegovy (Drug) $67,025
- Rybelsus (Drug) $58,350
- Ozempic (Drug) $33,825
- RYBELSUS (Drug) $21,200
- SURPASS (Device) $9,448
- SUBOXONE SUBLINGUAL FILM (Drug) $6,169
- Surpass (Device) $1,398
- FASENRA (Drug) $700.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Seattle
Dr. Pavle Repovic, Md, Phd, MD, PHD
Neurology — Payments: $1.2M
Neurology $1.2M
Nathaniel Watson, Md, MD
Neurology — Payments: $352,101
Neurology $352,101
Mariko Kita, Md, MD
Neurology — Payments: $243,050
Neurology $243,050
Christyn Edmundson, Md, MD
Neurology — Payments: $226,530
Neurology $226,530
Pravin Khemani, Md, MD
Neurology — Payments: $199,884
Neurology $199,884
Yince Loh, M.d, M.D
Neurology — Payments: $177,017
Neurology $177,017